LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $44.85M rose 304.9% year over year, ahead of the +263.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.5% from the prior quarter. Over 3 fiscal years it compounded at +175.2% a year.

Context

  • Selling, general & admin amounted to 476.0% of revenue in FY2025.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $23.83M (-73.8%) for the fiscal year ending Dec 2026, a slowdown from the +216.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$44.85M+13.5% QoQ
Last fiscal yearDec 2025
$90.85M+216.0% YoY
LTMMar 2026
$124.62M+263.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+304.9%-70.0%-374.9 pp
1 year+216.0%-73.8%-289.8 pp
3-year CAGR+175.2%+5.7%-169.5 pp
5-year CAGR+16.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
90.85M USD
Year-over-year change
+216.0%
4-year CAGR
+42.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +263.0% is the 2nd highest of 11, against a peer median of +14.8%.
  • Selling, general & admin amounts to 593.8% of revenue for LENZ, versus a peer median of 76.0%.
LENZ Competitors
Selling, General & Admin for LENZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$261.22M USD+825.5%+131.1%263.9%
GERNGeron CorporationLTM Mar 2026$154.66M USD-2.5%+54.0%78.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$152.74M USD-3.6%+9.9%73.2%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$124.62M USD+263.0%+175.2%593.8%
PRMEPrime Medicine, Inc.LTM Mar 2026$56.47M USD+8.0%+20.6%1399.8%
SVRASavara Inc.LTM Mar 2026$48.34M USD+69.0%+56.7%—
TYRATyra Biosciences, Inc.LTM Mar 2026$31.48M USD+21.6%+23.3%—
RZLTRezolute, Inc.LTM Mar 2026$27.59M USD+58.7%+25.2%—
GHRSGH Research PLCLTM Mar 2026$23.07M USD+35.6%+29.0%—
NBTXNanobiotix S.A.FY2025€20.22M EUR-1.5%+4.2%68.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$15.94M USD-39.5%-3.8%8.3%
Peer median (excluding LENZ) —+14.8%+24.2%76.0%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015M0019.09M
Cost of Revenue734K0058K705K
Gross Profit(734K)15M0(58K)18.38M
Gross Margin—100.0%——96.3%
Research & Development37.93M21.13M59.5M29.8M18.67M
Selling, General & Admin21.78M4.36M12.93M28.75M90.85M
Operating Expenses59.71M25.48M72.43M58.55M109.52M
Depreciation & Amortization734K8K15K58K287K
EBITDA(70.03M)(10.46M)(70.13M)(49.71M)(81.34M)
EBITDA Margin—-69.7%——-426.1%
Operating Income(60.44M)(10.48M)(72.43M)(58.61M)(91.14M)
Operating Margin—-69.9%——-477.5%
Interest Income002.19M8.55M9.76M
Interest Expense00000
Other Income / Expenses(10.32M)19K2.28M8.84M9.51M
Income Before Tax(70.76M)(10.46M)(70.15M)(49.77M)(81.63M)
Pre-Tax Margin—-69.8%——-427.6%
Income Tax Expense0347K(179K)1K502K
Net Income(70.76M)(10.81M)(69.97M)(49.77M)(82.13M)
Net Margin—-72.1%——-430.3%
EPS (Basic)(8.54)(12.89)(15.30)(2.34)(2.85)
EPS (Diluted)(8.54)(12.89)(15.30)(2.34)(2.85)
Weighted Avg Shares8.29M7.84M8.15M21.28M28.81M
Weighted Avg Shares (Diluted)8.29M7.84M8.15M21.28M28.81M

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.